Summary
28.29
-0.93
(-3.18%)
06/05/2026
IDEAYA Biosciences, Inc. (IDYA)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| -3.18 | -2.25 | -1.77 | -14.35 | -21.13 | 34.08 | 29.65 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Fundamental Ratings
| Category | Rating |
| Main Rating | C- |
| Recommended Rating | Strong Sell |
| DCF | Strong Sell |
| ROE | Strong Sell |
| ROA | Strong Sell |
| Debt/Equity | Neutral |
| P/E | Strong Sell |
| P/B | Sell |
Earnings
| Trading Data | ||
| Close | 28.29 | |
| Open | 29.22 | |
| High | 29.60 | |
| Low | 28.19 | |
| Volume | 710,928 | |
| Change | -0.93 | |
| Change % | -3.18 | |
| Avg Volume (20 Days) | 781,232 | |
| Volume/Avg Volume (20 Days) Ratio | 0.91 | |
| 52 Week Range | 20.50 - 39.28 | |
| Price vs 52 Week High | -27.98% | |
| Price vs 52 Week Low | 38.00% | |
| Range | -3.18 | |
| Gap Up/Down | -0.37 | |
Profitibility | ||
| Market Capitalization (Mln) | 2,699 | |
| Revenue per share | 2.5397 | |
| Net Income per share | -1.5790 | |
| Dividend Yield | 0.0000 | |
| Dividend Share | 0.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | -17.9161 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
06/03 06:00 EST - prnewswire.com
IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer
IDEAYA entered into a clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-RAS inhibitor, in MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma IDEAYA will sponsor the...
IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer
IDEAYA entered into a clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-RAS inhibitor, in MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma IDEAYA will sponsor the...
06/01 12:00 EST - gurufocus.com
IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late
IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Li
IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late
IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Li
06/01 11:00 EST - prnewswire.com
IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO
Darovasertib combination resulted in a statistically significant and clinically meaningful improvement in median PFS vs. investigator's choice of therapy (ICT) – 6.9 months vs.
IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO
Darovasertib combination resulted in a statistically significant and clinically meaningful improvement in median PFS vs. investigator's choice of therapy (ICT) – 6.9 months vs.
05/29 07:00 EST - gurufocus.com
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire SOUTH SAN FRANCI
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire SOUTH SAN FRANCI
05/26 19:04 EST - marketbeat.com
IDEAYA Biosciences Spotlights Darovasertib Win, FDA Review Path at Oncology Summit
IDEAYA Biosciences NASDAQ: IDYA executives highlighted recent clinical progress across the company's oncology pipeline during a fireside chat at TD Cowen's seventh annual Oncology Innovation Summit, with the discussion focused primarily on darovasertib combinations in uveal melanoma and several...
IDEAYA Biosciences Spotlights Darovasertib Win, FDA Review Path at Oncology Summit
IDEAYA Biosciences NASDAQ: IDYA executives highlighted recent clinical progress across the company's oncology pipeline during a fireside chat at TD Cowen's seventh annual Oncology Innovation Summit, with the discussion focused primarily on darovasertib combinations in uveal melanoma and several...
05/26 06:00 EST - prnewswire.com
IDEAYA Biosciences Announces Participation at the 2026 Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 26, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the following events at the 2026 Jefferies Global Healthcare...
IDEAYA Biosciences Announces Participation at the 2026 Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 26, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the following events at the 2026 Jefferies Global Healthcare...
05/25 07:07 EST - marketbeat.com
IDEAYA Biosciences Eyes Busy 2026 as Darovasertib Advances Toward FDA Filing
IDEAYA Biosciences NASDAQ: IDYA Chief Executive Yujiro Hata said the precision oncology company is preparing for a busy 2026, led by regulatory and clinical milestones for darovasertib in metastatic uveal melanoma and multiple data readouts across its pipeline.
IDEAYA Biosciences Eyes Busy 2026 as Darovasertib Advances Toward FDA Filing
IDEAYA Biosciences NASDAQ: IDYA Chief Executive Yujiro Hata said the precision oncology company is preparing for a busy 2026, led by regulatory and clinical milestones for darovasertib in metastatic uveal melanoma and multiple data readouts across its pipeline.
05/18 14:22 EST - prnewswire.com
B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic
/PRNewswire/ -- USA News Group News Commentary - For more than two decades, B7-H3 sat on the shortlist of theoretically perfect cancer drug targets that nobody
B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic
/PRNewswire/ -- USA News Group News Commentary - For more than two decades, B7-H3 sat on the shortlist of theoretically perfect cancer drug targets that nobody
05/18 00:06 EST - marketbeat.com
IDEAYA Biosciences Says Melanoma Drug on Track for NDA After Strong Trial Data
IDEAYA Biosciences NASDAQ: IDYA said its lead oncology program remains on track for a regulatory submission after reporting positive top-line data in first-line metastatic melanoma, while also highlighting several pipeline programs during a presentation at the Bank of America Global Healthcare...
IDEAYA Biosciences Says Melanoma Drug on Track for NDA After Strong Trial Data
IDEAYA Biosciences NASDAQ: IDYA said its lead oncology program remains on track for a regulatory submission after reporting positive top-line data in first-line metastatic melanoma, while also highlighting several pipeline programs during a presentation at the Bank of America Global Healthcare...
05/12 22:00 EST - seekingalpha.com
IDEAYA Biosciences, Inc. (IDYA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
IDEAYA Biosciences, Inc. (IDYA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
IDEAYA Biosciences, Inc. (IDYA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
IDEAYA Biosciences, Inc. (IDYA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
05/05 08:11 EST - zacks.com
IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates
IDEAYA Biosciences, Inc. (IDYA) came out with a quarterly loss of $1.11 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to a loss of $0.82 per share a year ago.
IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates
IDEAYA Biosciences, Inc. (IDYA) came out with a quarterly loss of $1.11 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to a loss of $0.82 per share a year ago.
05/05 06:00 EST - prnewswire.com
IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
Phase 2/3 registrational trial (OptimUM-02) of darovasertib combination met its primary endpoint; complete data will be provided in a late-breaking oral presentation at ASCO IDEAYA to initiate RTOR submission process with first pre-submission in May; targeting completion of the NDA filing in H2...
IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
Phase 2/3 registrational trial (OptimUM-02) of darovasertib combination met its primary endpoint; complete data will be provided in a late-breaking oral presentation at ASCO IDEAYA to initiate RTOR submission process with first pre-submission in May; targeting completion of the NDA filing in H2...
04/30 06:00 EST - prnewswire.com
IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program
Phase 2/3 registrational trial (OptimUM-02) of darovasertib combination met its primary endpoint and will be presented in a late-breaking oral presentation at ASCO 2026 IDEAYA to initiate the RTOR submission process with the first pre-submission in May, with completion of the NDA filing expected in...
IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program
Phase 2/3 registrational trial (OptimUM-02) of darovasertib combination met its primary endpoint and will be presented in a late-breaking oral presentation at ASCO 2026 IDEAYA to initiate the RTOR submission process with the first pre-submission in May, with completion of the NDA filing expected in...
04/21 10:15 EST - prnewswire.com
IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma
SOUTH SAN FRANCISCO, Calif., April 21, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced they have been selected for a late-breaking abstract (LBA) oral presentation to provide the complete data from the Phase 2/3...
IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma
SOUTH SAN FRANCISCO, Calif., April 21, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced they have been selected for a late-breaking abstract (LBA) oral presentation to provide the complete data from the Phase 2/3...
04/14 01:02 EST - defenseworld.net
IDEAYA Biosciences Unveils OptimUM-02 Data: Darovasertib/Crizotinib Doubles PFS in Uveal Melanoma
IDEAYA Biosciences (NASDAQ: IDYA) shared top-line results from its randomized phase II/III OptimUM-02 study evaluating darovasertib in combination with crizotinib as a frontline treatment for HLA-A2 negative metastatic uveal melanoma. The webcast featured prepared remarks from Founder, President,...
IDEAYA Biosciences Unveils OptimUM-02 Data: Darovasertib/Crizotinib Doubles PFS in Uveal Melanoma
IDEAYA Biosciences (NASDAQ: IDYA) shared top-line results from its randomized phase II/III OptimUM-02 study evaluating darovasertib in combination with crizotinib as a frontline treatment for HLA-A2 negative metastatic uveal melanoma. The webcast featured prepared remarks from Founder, President,...
04/13 12:11 EST - seekingalpha.com
IDEAYA Biosciences, Inc. (IDYA) Discusses Topline Results from OptimUM-02 Trial Evaluating Darovasertib and Crizotinib in HLA-A2-Negative Metastatic Uveal Melanoma Transcript
IDEAYA Biosciences, Inc. (IDYA) Discusses Topline Results from OptimUM-02 Trial Evaluating Darovasertib and Crizotinib in HLA-A2-Negative Metastatic Uveal Melanoma Transcript
IDEAYA Biosciences, Inc. (IDYA) Discusses Topline Results from OptimUM-02 Trial Evaluating Darovasertib and Crizotinib in HLA-A2-Negative Metastatic Uveal Melanoma Transcript
IDEAYA Biosciences, Inc. (IDYA) Discusses Topline Results from OptimUM-02 Trial Evaluating Darovasertib and Crizotinib in HLA-A2-Negative Metastatic Uveal Melanoma Transcript
04/13 07:48 EST - feeds.benzinga.com
IDEAYA Eye Cancer Trial Data Beats Standard Therapy, Stock Soars
IDEAYA shares rise after darovasertib trial shows progression-free survival benefit in uveal melanoma; NDA filing planned for 2026.
IDEAYA Eye Cancer Trial Data Beats Standard Therapy, Stock Soars
IDEAYA shares rise after darovasertib trial shows progression-free survival benefit in uveal melanoma; NDA filing planned for 2026.
04/13 07:21 EST - barrons.com
Ideaya Biosciences Stock Jumps 15% on Eye Cancer Therapy Trial Results
The California-based biotechnology company reports statistically significant results from a clinical trial evaluating its combination therapy for a rare eye cancer.
Ideaya Biosciences Stock Jumps 15% on Eye Cancer Therapy Trial Results
The California-based biotechnology company reports statistically significant results from a clinical trial evaluating its combination therapy for a rare eye cancer.
Market News
×
Loading news…